Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED HydrALAZINE Hydrochloride Tablets, USP 25 mg – round, convex, pink film coated tablet engraved with HP above 2 on one side and plain on the other side NDC 63187-901-30 Bottles of 30 NDC 63187-901-60 Bottles of 60 NDC 63187-901-90 Bottles of 90 Dispense in a tight, light-resistant container as defined in the USP. Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. MANUFACTURED FOR: Heritage Pharmaceuticals Inc Eatontown, NJ 077241-866-901-DRUG (3784) Repackaged by: Proficient Rx LP Thousand Oaks, CA 91320 Issued: 10/13; PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Hydralazine Hydrochloride Tablets, USP, 25 mg, 90 count 63187-901-90
- HOW SUPPLIED HydrALAZINE Hydrochloride Tablets, USP 25 mg – round, convex, pink film coated tablet engraved with HP above 2 on one side and plain on the other side NDC 63187-901-30 Bottles of 30 NDC 63187-901-60 Bottles of 60 NDC 63187-901-90 Bottles of 90 Dispense in a tight, light-resistant container as defined in the USP. Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. MANUFACTURED FOR: Heritage Pharmaceuticals Inc Eatontown, NJ 077241-866-901-DRUG (3784) Repackaged by: Proficient Rx LP Thousand Oaks, CA 91320 Issued: 10/13
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Hydralazine Hydrochloride Tablets, USP, 25 mg, 90 count 63187-901-90
Overview
HydrALAZINE hydrochloride, USP, is an antihypertensive, for oral administration. Its chemical name is 1-hydrazinophthalazine monohydrochloride, and its structural formula is: CHN·HCl HydrALAZINE hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275°C, with decomposition, and has a molecular weight of 196.64. Each tablet for oral administration contains 10 mg, 25 mg, 50 mg, or 100 mg hydrALAZINE hydrochloride, USP. Tablets also contain FD&C Red #40/Allura Red AC Aluminum Lake, hypromellose, lactose anhydrous, light mineral oil, microcrystalline cellulose, magnesium stearate, pregelatinized starch, sodium lauryl sulfate, and titanium dioxide. a9cb621b-figure-01
Indications & Usage
Essential hypertension, alone or as an adjunct.
Dosage & Administration
Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2 to 4 days, increase to 25 mg four times daily for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg four times daily. For maintenance, adjust dosage to the lowest effective levels. The incidence of toxic reactions, particularly the L.E. cell syndrome, is high in the group of patients receiving large doses of hydrALAZINE. In a few resistant patients, up to 300 mg of hydrALAZINE daily may be required for a significant antihypertensive effect. In such cases, a lower dosage of hydrALAZINE combined with a thiazide and/or reserpine or a beta blocker may be considered. However, when combining therapy, individual titration is essential to ensure the lowest possible therapeutic dose of each drug.[/S]
Warnings & Precautions
WARNINGS In a few patients hydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary. (See PRECAUTIONS, Laboratory Tests .)
Contraindications
Hypersensitivity to hydrALAZINE; coronary artery disease; mitral valvular rheumatic heart disease.
Adverse Reactions
Adverse reactions with hydrALAZINE are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug. The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency. Common: Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris. Less Frequent: Digestive: constipation, paralytic ileus. Cardiovascular : hypotension, paradoxical pressor response, edema. Respiratory : dyspnea. Neurologic : peripheral neuritis, evidenced by paresthesia, numbness, and tingling; dizziness; tremors; muscle cramps; psychotic reactions characterized by depression, disorientation, or anxiety. Genitourinary: difficulty in urination. Hematologic: blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura; lymphadenopathy; splenomegaly. Hypersensitive Reactions: rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and rarely, hepatitis. Other: nasal congestion, flushing, lacrimation, conjunctivitis.
Drug Interactions
Drug /Drug Interactions MAO inhibitors should be used with caution in patients receiving hydrALAZINE . When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydrALAZINE, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when diazoxide injection and hydrALAZINE are used concomitantly. Drug/Food Interactions Administration of hydrALAZINE with food results in higher plasma levels.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.